PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment Extension
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Scalp Psoriasis
Conditions
Scalp Psoriasis
Trial Timeline
Mar 29, 2019 → Feb 17, 2022
NCT ID
NCT03897088About PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment Extension
PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment Extension is a phase 3 stage product being developed by Sun Pharmaceutical for Scalp Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03897088. Target conditions include Scalp Psoriasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03897088 | Phase 3 | Completed |
Competing Products
7 competing products in Scalp Psoriasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DSXS topical product | Sun Pharmaceutical | Phase 2 | 52 |
| DSXS + Placebo | Sun Pharmaceutical | Phase 3 | 77 |
| DSXS topical + Vehicle topical | Sun Pharmaceutical | Phase 3 | 77 |
| Betamethasone Scalp Suspension 0.064%;0.0005% + Taclonex® + Placebo topical suspension | Sun Pharmaceutical | Phase 1 | 33 |
| Calcipotriene/Betamethasone Dipropionate + Taclonex® + Placebo | Glenmark Pharmaceuticals | Phase 3 | 77 |
| Secukinumab 300 mg + Placebo | Novartis | Phase 3 | 77 |
| Roflumilast Foam 0.3% + Vehicle Foam | Arcutis Biotherapeutics | Phase 3 | 72 |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85